Published in Endocrinology on May 10, 2007
Role of mitochondrial dysfunction in insulin resistance. Circ Res (2008) 3.45
Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res (2012) 3.02
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med (2009) 2.25
NOX enzymes as novel targets for drug development. Semin Immunopathol (2008) 1.90
Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med (Berl) (2010) 1.90
Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol (2010) 1.35
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension (2010) 1.32
NOX enzymes and pulmonary disease. Antioxid Redox Signal (2009) 1.29
Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol (2013) 1.22
Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol (2010) 1.21
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology (2008) 1.21
Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology (2009) 1.18
Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol (2009) 1.18
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab (2008) 1.15
Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat Rev Cardiol (2010) 1.13
Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes (2010) 1.12
Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis (2010) 1.12
Exercise in the metabolic syndrome. Oxid Med Cell Longev (2012) 1.11
Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol (2009) 1.04
Oxidative stress in the cardiorenal metabolic syndrome. Curr Hypertens Rep (2012) 1.02
Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol (2011) 1.02
Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension (2008) 0.99
The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep (2012) 0.97
Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch (2008) 0.92
Targeting NOX enzymes in pulmonary fibrosis. Cell Mol Life Sci (2012) 0.92
Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol (2009) 0.88
Alteration of energy substrates and ROS production in diabetic cardiomyopathy. Mediators Inflamm (2013) 0.88
Possible Mechanisms of Local Tissue Renin-Angiotensin System Activation in the Cardiorenal Metabolic Syndrome and Type 2 Diabetes Mellitus. Cardiorenal Med (2011) 0.87
Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. J Am Soc Hypertens (2008) 0.85
Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling. Metabolism (2013) 0.82
Aldosterone and cardiovascular disease: the heart of the matter. Trends Endocrinol Metab (2012) 0.82
Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells. Endocrinology (2010) 0.82
Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor. Int J Hypertens (2011) 0.81
Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction. Circ Heart Fail (2014) 0.81
NADPH oxidases in lung health and disease. Antioxid Redox Signal (2014) 0.81
Aldosterone and the heart: still an unresolved issue? Front Endocrinol (Lausanne) (2014) 0.79
Salt loading exacerbates diastolic dysfunction and cardiac remodeling in young female Ren2 rats. Metabolism (2013) 0.79
NADPH oxidase enzymes in skin fibrosis: molecular targets and therapeutic agents. Arch Dermatol Res (2013) 0.79
Ultrastructure Study of Transgenic Ren2 Rat Aorta - Part 1: Endothelium and Intima. Cardiorenal Med (2012) 0.77
Treatment of Primary Aldosteronism and Organ Protection. Int J Endocrinol (2015) 0.75
Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction. Biochim Biophys Acta (2016) 0.75
Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis. J Am Heart Assoc (2016) 0.75
Heart failure with preserved ejection fraction: a nephrologist-directed primer. Heart Fail Rev (2017) 0.75
Metformin: an update. Ann Intern Med (2002) 5.62
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Role of mitochondrial dysfunction in insulin resistance. Circ Res (2008) 3.45
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med (2009) 2.25
Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol (2010) 2.09
Rats selectively bred for low aerobic capacity have reduced hepatic mitochondrial oxidative capacity and susceptibility to hepatic steatosis and injury. J Physiol (2009) 1.95
Hypertension, angiotensin II, and oxidative stress. N Engl J Med (2002) 1.92
Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med (Berl) (2010) 1.90
Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum Mol Genet (2010) 1.76
Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol (2002) 1.76
Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol (2004) 1.73
Sex differences in the development of angiotensin II-induced hypertension in conscious mice. Am J Physiol Heart Circ Physiol (2004) 1.72
Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens (2003) 1.71
CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.71
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol (2007) 1.71
Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol (2011) 1.69
Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol (2007) 1.68
Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine (2004) 1.64
Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem (2006) 1.62
Estrogen receptor-β in the paraventricular nucleus and rostroventrolateral medulla plays an essential protective role in aldosterone/salt-induced hypertension in female rats. Hypertension (2013) 1.61
Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc (2006) 1.60
Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol (2005) 1.59
Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care (2002) 1.59
Estrogen receptor-alpha mediates estrogen protection from angiotensin II-induced hypertension in conscious female mice. Am J Physiol Heart Circ Physiol (2006) 1.59
AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension (2003) 1.57
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis (2009) 1.52
Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich) (2005) 1.51
ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich) (2008) 1.50
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol (2008) 1.48
Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev (2010) 1.47
Epidemiology of diabetes. J Clin Pharmacol (2004) 1.47
Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab (2007) 1.46
Redox control of renal function and hypertension. Antioxid Redox Signal (2008) 1.45
Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes (2013) 1.45
Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. Nutr Metab (Lond) (2008) 1.44
Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model. Am J Physiol Gastrointest Liver Physiol (2011) 1.41
Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol (2007) 1.39
No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney Int (2013) 1.38
Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab (2007) 1.36
The Role of Overweight and Obesity in the Cardiorenal Syndrome. Cardiorenal Med (2011) 1.35
Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab (2004) 1.33
NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension (2007) 1.32
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension (2010) 1.32
Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun (2003) 1.31
Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol (2006) 1.30
The metabolic syndrome: role of skeletal muscle metabolism. Ann Med (2006) 1.28
Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism (2013) 1.27
Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab (2011) 1.25
The role of oxidative stress in the metabolic syndrome. Rev Cardiovasc Med (2011) 1.23
Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension (2008) 1.23
Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep (2004) 1.22
Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab (2008) 1.22
Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol (2010) 1.21
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology (2008) 1.21
Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci (2012) 1.21
Hypertension and obesity. Recent Prog Horm Res (2004) 1.20
Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord (2013) 1.19
Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet. Endocrinology (2013) 1.19
Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol (2009) 1.18
Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology (2009) 1.18